Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma

Alvaro J. Alencar, Craig Moskowitz

Research output: Contribution to journalComment/debate

Abstract

The addition of the immune-checkpoint inhibitor nivolumab to first-line therapy with doxorubicin, vinblastine and dacarbazine seems feasible, with no signals of severe additional toxicities emerging. The high response rates and acceptable safety profile might make this combination an appealing alternative in the treatment of patients with high-risk disease.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hodgkin Disease
Dacarbazine
Vinblastine
Doxorubicin
Safety
Therapeutics
nivolumab

ASJC Scopus subject areas

  • Oncology

Cite this

Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma. / Alencar, Alvaro J.; Moskowitz, Craig.

In: Nature Reviews Clinical Oncology, 01.01.2019.

Research output: Contribution to journalComment/debate

@article{5b359e302a234607885e725a1eb74596,
title = "Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma",
abstract = "The addition of the immune-checkpoint inhibitor nivolumab to first-line therapy with doxorubicin, vinblastine and dacarbazine seems feasible, with no signals of severe additional toxicities emerging. The high response rates and acceptable safety profile might make this combination an appealing alternative in the treatment of patients with high-risk disease.",
author = "Alencar, {Alvaro J.} and Craig Moskowitz",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41571-019-0255-8",
language = "English (US)",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma

AU - Alencar, Alvaro J.

AU - Moskowitz, Craig

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The addition of the immune-checkpoint inhibitor nivolumab to first-line therapy with doxorubicin, vinblastine and dacarbazine seems feasible, with no signals of severe additional toxicities emerging. The high response rates and acceptable safety profile might make this combination an appealing alternative in the treatment of patients with high-risk disease.

AB - The addition of the immune-checkpoint inhibitor nivolumab to first-line therapy with doxorubicin, vinblastine and dacarbazine seems feasible, with no signals of severe additional toxicities emerging. The high response rates and acceptable safety profile might make this combination an appealing alternative in the treatment of patients with high-risk disease.

UR - http://www.scopus.com/inward/record.url?scp=85069466905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069466905&partnerID=8YFLogxK

U2 - 10.1038/s41571-019-0255-8

DO - 10.1038/s41571-019-0255-8

M3 - Comment/debate

C2 - 31308512

AN - SCOPUS:85069466905

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -